Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis

H. Ballentine Carter, Alan W. Partin, Albert A. Luderer, E. Metter, Patricia Landis, Daniel W. Chan, James L. Fozard, Jay D. Pearson

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Objectives. To evaluate serial measurements of free and total prostate- specific antigen (PSA) as a predictor of prostate cancer aggressiveness. Methods. Twenty men diagnosed with adenocarcinoma of the prostate in the pre- PSA era had serum PSA measurements made on multiple stored frozen sera samples available for up to 18 years prior to diagnosis. Subjects were categorized as having aggressive cancer (n = 12) based on the presence of clinical Stage T3, or nodal or bone metastases (N+, M+), or pathologic positive-margin disease, or a Gleason score of 7 or greater; nonaggressive cancer (n = 8) was identified by the absence of these criteria. Results. There was no statistically significant difference in free PSA levels among men with aggressive and nonaggressive prostate cancers from 0 to 15 years before diagnosis. Total PSA levels were significantly different between the groups by 5 years before diagnosis (P = 0.04). At a time when total PSA levels were not different between groups (10 years before diagnosis), there was a statistically significant difference in the percentage of free PSA between aggressive and nonaggressive cancers (P = 0.008). Among 14 men who had sera available for analysis at 10 years before diagnosis, all 8 men with aggressive cancers had a percent free PSA of 0.14 or less; this compares with only 2 of 6 men (33%) with nonaggressive cancer. Conclusions. These data suggest that the percentage of free PSA in sera is predictive of tumor behavior at a time when total PSA levels provide no information on tumor aggressiveness. Evaluation of the percentage of free serum PSA may be helpful in making the decision between expectant management and treatment for those men who are diagnosed with early prostate cancers by PSA testing.

Original languageEnglish (US)
Pages (from-to)379-384
Number of pages6
JournalUrology
Volume49
Issue number3
DOIs
StatePublished - May 1 1997
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Serum
Neoplasms
Prostatic Neoplasms
Prostate Cancer, Hereditary, 7
Neoplasm Grading
Prostate
Decision Making
Adenocarcinoma
Neoplasm Metastasis
Bone and Bones

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. / Carter, H. Ballentine; Partin, Alan W.; Luderer, Albert A.; Metter, E.; Landis, Patricia; Chan, Daniel W.; Fozard, James L.; Pearson, Jay D.

In: Urology, Vol. 49, No. 3, 01.05.1997, p. 379-384.

Research output: Contribution to journalArticle

Carter, HB, Partin, AW, Luderer, AA, Metter, E, Landis, P, Chan, DW, Fozard, JL & Pearson, JD 1997, 'Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis', Urology, vol. 49, no. 3, pp. 379-384. https://doi.org/10.1016/S0090-4295(96)00629-2
Carter, H. Ballentine ; Partin, Alan W. ; Luderer, Albert A. ; Metter, E. ; Landis, Patricia ; Chan, Daniel W. ; Fozard, James L. ; Pearson, Jay D. / Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. In: Urology. 1997 ; Vol. 49, No. 3. pp. 379-384.
@article{d10b100839104d1aa93204f0c60c67ed,
title = "Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis",
abstract = "Objectives. To evaluate serial measurements of free and total prostate- specific antigen (PSA) as a predictor of prostate cancer aggressiveness. Methods. Twenty men diagnosed with adenocarcinoma of the prostate in the pre- PSA era had serum PSA measurements made on multiple stored frozen sera samples available for up to 18 years prior to diagnosis. Subjects were categorized as having aggressive cancer (n = 12) based on the presence of clinical Stage T3, or nodal or bone metastases (N+, M+), or pathologic positive-margin disease, or a Gleason score of 7 or greater; nonaggressive cancer (n = 8) was identified by the absence of these criteria. Results. There was no statistically significant difference in free PSA levels among men with aggressive and nonaggressive prostate cancers from 0 to 15 years before diagnosis. Total PSA levels were significantly different between the groups by 5 years before diagnosis (P = 0.04). At a time when total PSA levels were not different between groups (10 years before diagnosis), there was a statistically significant difference in the percentage of free PSA between aggressive and nonaggressive cancers (P = 0.008). Among 14 men who had sera available for analysis at 10 years before diagnosis, all 8 men with aggressive cancers had a percent free PSA of 0.14 or less; this compares with only 2 of 6 men (33{\%}) with nonaggressive cancer. Conclusions. These data suggest that the percentage of free PSA in sera is predictive of tumor behavior at a time when total PSA levels provide no information on tumor aggressiveness. Evaluation of the percentage of free serum PSA may be helpful in making the decision between expectant management and treatment for those men who are diagnosed with early prostate cancers by PSA testing.",
author = "Carter, {H. Ballentine} and Partin, {Alan W.} and Luderer, {Albert A.} and E. Metter and Patricia Landis and Chan, {Daniel W.} and Fozard, {James L.} and Pearson, {Jay D.}",
year = "1997",
month = "5",
day = "1",
doi = "10.1016/S0090-4295(96)00629-2",
language = "English (US)",
volume = "49",
pages = "379--384",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis

AU - Carter, H. Ballentine

AU - Partin, Alan W.

AU - Luderer, Albert A.

AU - Metter, E.

AU - Landis, Patricia

AU - Chan, Daniel W.

AU - Fozard, James L.

AU - Pearson, Jay D.

PY - 1997/5/1

Y1 - 1997/5/1

N2 - Objectives. To evaluate serial measurements of free and total prostate- specific antigen (PSA) as a predictor of prostate cancer aggressiveness. Methods. Twenty men diagnosed with adenocarcinoma of the prostate in the pre- PSA era had serum PSA measurements made on multiple stored frozen sera samples available for up to 18 years prior to diagnosis. Subjects were categorized as having aggressive cancer (n = 12) based on the presence of clinical Stage T3, or nodal or bone metastases (N+, M+), or pathologic positive-margin disease, or a Gleason score of 7 or greater; nonaggressive cancer (n = 8) was identified by the absence of these criteria. Results. There was no statistically significant difference in free PSA levels among men with aggressive and nonaggressive prostate cancers from 0 to 15 years before diagnosis. Total PSA levels were significantly different between the groups by 5 years before diagnosis (P = 0.04). At a time when total PSA levels were not different between groups (10 years before diagnosis), there was a statistically significant difference in the percentage of free PSA between aggressive and nonaggressive cancers (P = 0.008). Among 14 men who had sera available for analysis at 10 years before diagnosis, all 8 men with aggressive cancers had a percent free PSA of 0.14 or less; this compares with only 2 of 6 men (33%) with nonaggressive cancer. Conclusions. These data suggest that the percentage of free PSA in sera is predictive of tumor behavior at a time when total PSA levels provide no information on tumor aggressiveness. Evaluation of the percentage of free serum PSA may be helpful in making the decision between expectant management and treatment for those men who are diagnosed with early prostate cancers by PSA testing.

AB - Objectives. To evaluate serial measurements of free and total prostate- specific antigen (PSA) as a predictor of prostate cancer aggressiveness. Methods. Twenty men diagnosed with adenocarcinoma of the prostate in the pre- PSA era had serum PSA measurements made on multiple stored frozen sera samples available for up to 18 years prior to diagnosis. Subjects were categorized as having aggressive cancer (n = 12) based on the presence of clinical Stage T3, or nodal or bone metastases (N+, M+), or pathologic positive-margin disease, or a Gleason score of 7 or greater; nonaggressive cancer (n = 8) was identified by the absence of these criteria. Results. There was no statistically significant difference in free PSA levels among men with aggressive and nonaggressive prostate cancers from 0 to 15 years before diagnosis. Total PSA levels were significantly different between the groups by 5 years before diagnosis (P = 0.04). At a time when total PSA levels were not different between groups (10 years before diagnosis), there was a statistically significant difference in the percentage of free PSA between aggressive and nonaggressive cancers (P = 0.008). Among 14 men who had sera available for analysis at 10 years before diagnosis, all 8 men with aggressive cancers had a percent free PSA of 0.14 or less; this compares with only 2 of 6 men (33%) with nonaggressive cancer. Conclusions. These data suggest that the percentage of free PSA in sera is predictive of tumor behavior at a time when total PSA levels provide no information on tumor aggressiveness. Evaluation of the percentage of free serum PSA may be helpful in making the decision between expectant management and treatment for those men who are diagnosed with early prostate cancers by PSA testing.

UR - http://www.scopus.com/inward/record.url?scp=0030933344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030933344&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(96)00629-2

DO - 10.1016/S0090-4295(96)00629-2

M3 - Article

VL - 49

SP - 379

EP - 384

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -